TY - JOUR
T1 - Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients
AU - Lo Re, Vincent
AU - Frank, Ian
AU - Gross, Robert
AU - Synnestvedt, Marie
AU - Localio, A. Russell
AU - Kostman, Jay R.
AU - Strom, Brian L.
N1 - Funding Information:
Funding Sources: This investigation was supported by NIH research grant F32-DK069080 (Dr. Lo Re), NIH research grant K08-MH01584 (Dr. Gross), the Penn AIDS Clinical Trial Unit U01-AI32783 (Drs. Frank, Gross, and Kostman), the University of Pennsylvania Center for AIDS Research grant P30-AI45008 (Drs. Frank and Gross), and an Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics cooperative agreement (grant #HS10399).
PY - 2007/3
Y1 - 2007/3
N2 - Objective: To determine the validity of self-reported hepatitis B virus (HBV) and hepatitis C virus (HCV) in HIV-infected injection drug users (IDUs) vs. nonIDUs. Methods: A cross-sectional study was performed among HIV-infected IDUs and nonIDUs in the Penn Center for AIDS Research (CFAR) Database. Self-reported past HBV, HCV, and serostatus were obtained from the CFAR Database. Results: Among 970 subjects (798 nonIDUs; 172 IDUs), there was no difference in sensitivity of self-reported HBV between nonIDUs (27% [95/346]; 95% CI, 23%-32%) and IDUs (26% [31/117]; 95% CI, 19%-35%; P > 0.5), but specificity was greater among nonIDUs (96% [360/374; 95% CI, 94%-98%] vs. 78% [28/36; 95% CI, 61%-90%]; P < 0.001). Sensitivity of self-reported HCV was greater among IDUs (78% [101/130; 95% CI, 70%-85%] vs. 62% [47/76; 95% CI, 50%-73%]; P = 0.02), but there was no difference in specificity (97% [626/643]; 95% CI, 96%-98% for nonIDUs vs. 93% [26/28]; 95% CI, 76%-99%] for IDUs; P = 0.2). Conclusions: The sensitivity of self-reported HBV and HCV compared to actual serostatus are not sufficiently high enough to warrant their use to estimate the prevalence and incidence of these infections.
AB - Objective: To determine the validity of self-reported hepatitis B virus (HBV) and hepatitis C virus (HCV) in HIV-infected injection drug users (IDUs) vs. nonIDUs. Methods: A cross-sectional study was performed among HIV-infected IDUs and nonIDUs in the Penn Center for AIDS Research (CFAR) Database. Self-reported past HBV, HCV, and serostatus were obtained from the CFAR Database. Results: Among 970 subjects (798 nonIDUs; 172 IDUs), there was no difference in sensitivity of self-reported HBV between nonIDUs (27% [95/346]; 95% CI, 23%-32%) and IDUs (26% [31/117]; 95% CI, 19%-35%; P > 0.5), but specificity was greater among nonIDUs (96% [360/374; 95% CI, 94%-98%] vs. 78% [28/36; 95% CI, 61%-90%]; P < 0.001). Sensitivity of self-reported HCV was greater among IDUs (78% [101/130; 95% CI, 70%-85%] vs. 62% [47/76; 95% CI, 50%-73%]; P = 0.02), but there was no difference in specificity (97% [626/643]; 95% CI, 96%-98% for nonIDUs vs. 93% [26/28]; 95% CI, 76%-99%] for IDUs; P = 0.2). Conclusions: The sensitivity of self-reported HBV and HCV compared to actual serostatus are not sufficiently high enough to warrant their use to estimate the prevalence and incidence of these infections.
KW - HIV, Hepatitis B, Hepatitis C, HIV/hepatitis B virus coinfection
KW - HIV/hepatitis C virus coinfection
KW - Self-report
KW - Validity
UR - http://www.scopus.com/inward/record.url?scp=33846815039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846815039&partnerID=8YFLogxK
U2 - 10.1016/j.jclinepi.2006.06.020
DO - 10.1016/j.jclinepi.2006.06.020
M3 - Article
C2 - 17292024
AN - SCOPUS:33846815039
SN - 0895-4356
VL - 60
SP - 294
EP - 299
JO - Journal of Chronic Diseases
JF - Journal of Chronic Diseases
IS - 3
ER -